Abstract
There has been an increase in understanding molecular biology of malignant pleural mesothelioma. This resulted in more clinical trials of novel therapeutic approaches. The more conventional systemic treatments for malignant mesothelioma are based on the use of Cisplatin and Pemetrexed. The newer agents such as vorinostat an Histone deacetylase inhibitor, focal adhesion kinase inhibitor Defactinib, mTOR inhibitor Everolimus, Bevacizumab a monoclonal antibody directed against Vascular Endothelial Growth Factor, immune check-point inhibitors, mesothelin targeted antibodies, Amatuximab have been investigated for their potential role in treatment of malignant mesothelioma. The role of radiation therapy in the curative treatment of malignant pleural mesothelioma has not been conclusively determined. In this review we will discuss the application of both radical and palliative radiotherapy in the context of managing of malignant mesothelioma.
Keywords: Chemotherapy, malignant mesothelioma, radiotherapy.
Current Respiratory Medicine Reviews
Title:The Role of Systemic Treatment and Radiotherapy in Malignant Mesothelioma
Volume: 12 Issue: 3
Author(s): Michael Lind, Rachael Barton, Andrzej Wieczorek, Mahmoud Loubani and Jack A. Kastelik
Affiliation:
Keywords: Chemotherapy, malignant mesothelioma, radiotherapy.
Abstract: There has been an increase in understanding molecular biology of malignant pleural mesothelioma. This resulted in more clinical trials of novel therapeutic approaches. The more conventional systemic treatments for malignant mesothelioma are based on the use of Cisplatin and Pemetrexed. The newer agents such as vorinostat an Histone deacetylase inhibitor, focal adhesion kinase inhibitor Defactinib, mTOR inhibitor Everolimus, Bevacizumab a monoclonal antibody directed against Vascular Endothelial Growth Factor, immune check-point inhibitors, mesothelin targeted antibodies, Amatuximab have been investigated for their potential role in treatment of malignant mesothelioma. The role of radiation therapy in the curative treatment of malignant pleural mesothelioma has not been conclusively determined. In this review we will discuss the application of both radical and palliative radiotherapy in the context of managing of malignant mesothelioma.
Export Options
About this article
Cite this article as:
Lind Michael, Barton Rachael, Wieczorek Andrzej, Loubani Mahmoud and Kastelik A. Jack, The Role of Systemic Treatment and Radiotherapy in Malignant Mesothelioma, Current Respiratory Medicine Reviews 2016; 12 (3) . https://dx.doi.org/10.2174/1573398X12666160919115534
DOI https://dx.doi.org/10.2174/1573398X12666160919115534 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis
Current Angiogenesis (Discontinued) Meet Our Editorial Board Member:
Current Respiratory Medicine Reviews T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Merlin, a “Magic” Linker Between the Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival
Current Protein & Peptide Science HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases
Current Pharmaceutical Design Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy
Current Drug Metabolism Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Mucosal T Cell Proliferation and Apoptosis in Inflammatory Bowel Disease
Current Drug Targets Onconeural Versus Paraneoplastic Antigens?
Current Medicinal Chemistry Platinum-Based Agents for Individualized Cancer Treatment
Current Molecular Medicine EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Hyaluronan and Hyaluronan Synthases: Potential Therapeutic Targets in Cancer
Current Drug Targets - Cardiovascular & Hematological Disorders Design, Synthesis and In-Vitro Cytotoxicity of Novel Platinum (II) Complexes with Phthalate as the Leaving Group
Letters in Drug Design & Discovery Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Potential of Taming MicroRNA on Driver Seat to Control Mitochondrial Horses in Breast Carcinoma
MicroRNA Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Current Cancer Drug Targets